Latest Revenue Growth News

Microba Life Sciences reports robust year-on-year growth in microbiome testing volumes and revenue, advancing towards regional break-even in Australia and the UK while progressing its therapeutic pipeline.

dorsaVi reports strong US commercial growth with over 100 new physical therapy sites and a 50% rise in cash receipts, alongside a strategic leadership change and breakthrough neuromorphic technology acquisition.

Acrux Limited reports solid revenue growth and increased cash reserves in the December quarter, driven by expanding its topical generics portfolio in the US and strategic moves into female Hormone Replacement Therapy.

PainChek has secured FDA-regulated medical device status, enabling US Remote Therapeutic Monitoring reimbursement and opening a major US growth avenue. The company targets musculoskeletal pain management in non-verbal dementia patients, a largely underserved market.

Nova Eye Medical has reported a record US$6.1 million in global sales for the December 2025 quarter, marking a 38% year-on-year increase and strong momentum across key markets. The company’s innovative iTrack™ technology continues to drive growth, supported by expanded manufacturing capacity and advancing clinical programs.

Sea Forest Limited has exceeded its breakeven target for its methane-reducing feed additive SeaFeed™, securing commitments for over 118,000 cattle and expanding commercial trials with major industry partners.

De.mem Limited has reported its strongest December quarter yet, with record cash receipts and a positive operating cash flow for the full year, underpinned by recurring revenues and strategic expansion into the gold mining sector.

Change Financial Limited has reported a record revenue quarter driven by its Vertexon platform growth and new client wins, prompting an upgrade to its FY26 financial guidance.

Vitasora Health Limited reported a significant 22% increase in daily clinical billing productivity for the December 2025 quarter, alongside a 17% rise in operating revenue. With new CMS reimbursement policies now in effect, the company anticipates a further 10–20% revenue uplift in 2026.

Doctor Care Anywhere reported steady consultation growth and a third consecutive quarter of positive cashflow in Q4 2025, while advancing digital health pilots and reaffirming ambitious medium-term revenue and profitability goals.

ImpediMed reported a solid Q2 FY26 with $3.9 million in revenue and significant reimbursement gains for its lymphoedema technology, while launching new US Heart Health and Wellness initiatives.

ikeGPS Group has reported a robust 35% increase in its platform subscription revenue exit run rate for the nine months to December 2025, reaffirming its FY26 growth guidance amid strong market demand and new AI-driven product launches.